In addition, there was a near‐significant trend toward a reduced risk of headache with GLP‐1 or GIP/GLP‐1 RA treatment (RR: 0.61; 95% CI: 0.34 to 1.07; p = 0.08; 2 studies; I2 = 93%; p for Cochran's Q < 0.01; Figure 1c). This evidence concerns the gene GIP and Headache.